Michael J. Rossi Sells 3,917 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Stock

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) CEO Michael J. Rossi sold 3,917 shares of the business’s stock in a transaction on Friday, March 7th. The shares were sold at an average price of $5.20, for a total value of $20,368.40. Following the completion of the sale, the chief executive officer now owns 137,083 shares of the company’s stock, valued at $712,831.60. This trade represents a 2.78 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Y-mAbs Therapeutics Trading Down 0.6 %

YMAB opened at $4.91 on Thursday. The company has a market cap of $222.02 million, a P/E ratio of -9.09 and a beta of 0.65. The business’s 50-day moving average price is $6.16 and its 200-day moving average price is $10.32. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.25 and a 12 month high of $17.78.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The company had revenue of $26.50 million during the quarter, compared to analysts’ expectations of $26.70 million. During the same quarter in the prior year, the firm posted ($0.02) EPS. Equities research analysts forecast that Y-mAbs Therapeutics, Inc. will post -0.65 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Paradigm Biocapital Advisors LP boosted its position in Y-mAbs Therapeutics by 3.7% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 4,236,346 shares of the company’s stock valued at $33,171,000 after acquiring an additional 150,000 shares in the last quarter. Acorn Capital Advisors LLC bought a new stake in shares of Y-mAbs Therapeutics in the 4th quarter worth approximately $22,408,000. Caligan Partners LP raised its holdings in Y-mAbs Therapeutics by 47.9% in the 4th quarter. Caligan Partners LP now owns 1,767,982 shares of the company’s stock worth $13,843,000 after acquiring an additional 572,729 shares during the last quarter. State Street Corp raised its holdings in Y-mAbs Therapeutics by 50.4% in the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after acquiring an additional 405,169 shares during the last quarter. Finally, Geode Capital Management LLC raised its holdings in Y-mAbs Therapeutics by 1.1% in the 4th quarter. Geode Capital Management LLC now owns 822,309 shares of the company’s stock worth $6,440,000 after acquiring an additional 8,820 shares during the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on YMAB. HC Wainwright restated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Bank of America lowered their target price on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Oppenheimer began coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They issued an “outperform” rating and a $23.00 price target on the stock. Wedbush restated an “outperform” rating and set a $23.00 target price on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. Finally, Brookline Capital Management started coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $19.30.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.